TLTanshi Li

Tanshi Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tanshi Li has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Enlightenment and lesson from the successful treatment of acute superior mesenteric artery embolism

    by Bei Wang, Rongju Sun, Wei Chen, Tanshi Li

    Despite recent advances, treatment of acute superior mesenteric artery embolism (SMAE) in emergency is still very difficult. The comparative rarity, the difficulty of early diagnosis, and the extremely high mortality of SMAE give us the sufficient reasons to report our successful experience in curing a patient with acute SMAE. In the present case, the patient was diagnosed early without evidence of intestinal necrosis. The diagnosis of SMAE was verified by computed tomography angiography (CTA). A comprehensive treatment was immediately employed including a combination of intra-arterial thrombolysis and embolectomy operation with emergent laparotomy. We summarize that the successful treatment of superior mesenteric artery embolism depends on early diagnosis and timely reestablishment of arterial flow under the support of general treatments such as prevention of sepsis and control of organic insufficiencies. Through a combined treatment, patient's life could be saved without complications.


    • 1 April 2012
      • Vol. 26  (4) , 483-8

    [Changes of microRNA and target gene expression levels in osteogenic differentiation of human bone marrow mesenchymal stem cells].

    by Junqiang Wei, Boxun Zhang, Xiaofei Zheng, Hua Chen, Xuezhong' Tian, Peifu Tang, Qing Song, Tanshi Li

    To clarify the trends of expression levels of several up-regulated micro RNA (miRNA) in tissues of atrophic bone nonunion and mRNAs and proteins of their related target genes in osteogenic differentiation of human bone marrow mesenchymal stem cells (hBMSCs), and to explore their biological functions. The hBMSCs were isolated from bone marrow of iliac bone by gradient centrifugation, and cultured. Osteogenic culture medium was used for osteogenic differentiation of the 4th generation of hBMSCs. The changes of corresponding miRNAs, mRNA and protein expression levels of related target genes were observed at 0 hour, 12 hours, 1 day, 2 days, 4 days, 7 days, and 14 days, by quantitative real-time PCR and Western blot. In the process of hBMSCs osteogenic differentiation, the mRNA and protein expression levels of osteoblastic target genes [alkaline phosphatase liver/bone/kidney (ALPL), bone morphogenetic protein 2 (BMP-2), and platelet-derived factor alpha polypeptide (PDGF-A)] at most time points increased significantly when compared with the values at 0 hour except that of BMP-2 decreased at 12 hours and 1 day, with maximum changes at 1 to 7 days. The miRNA expression levels, mRNA and protein expression levels changed significantly at different time points, while the trends of hsa-miRNA-149 and hsa-miRNA-654-5p changes were negatively correlated with the trends of ALPL and BMP-2 mRNA and protein expression changes respectively (P < 0.05). There was no obviously negative correlation between the trends of hsa-miRNA-221 change and PDGF-A change (P > 0.05). In the osteogenic differentiation process of hBMSCs, hsa-miRNA-149* and hsa-miRNA-654-5p are closely related with the mRNA and protein regulation of ALPL and BMP-2, respectively.

    • 1 March 2012
      • Vol. 32  (3) , 291-5

    [Hsa-miR-654-5p regulates osteogenic differentiation of human bone marrow mesenchymal stem cells by repressing bone morphogenetic protein 2].

    by Jun-Qiang Wei, Hua Chen, Xiao-Fei Zheng, Bo-Xun Zhang, Yan Wang, Pei-Fu Tang, Fei She, Qing Song, Tan-Shi Li

    To study the effect of hsa-miR-654-5p in repressing bone morphogenetic protein 2 (BMP2) mRNA and protein in human bone marrow mesenchymal stem cells (hBMSCs), and explore its regulatory role in osteogenic differentiation of hBMSCs. hBMSCs in the 4th passage were cultured for 16 h and transfected with hsa-miR-654-5p followed by further culture for 48 h. qRT-PCR and Western blotting were performed to detect the expressions of BMP2 mRNA and protein. Dual-luciferase?reporter gene assay was employed to examine the repression of the BMP2 gene. BMP2 mRNA and protein expressions were significantly down-regulated in hBMSCs with hsa-miR-654-5p overexpression. Dualluci-ferase reporter gene assay indicated that the predicted target site of BMP2 was repressed directly by hsa-miR-654-5p, but this repression did not occur at the mutant predicted target site of BMP2. hsa-miR-654-5p can directly repress the mRNA and protein expressions of BMP2 by binding to a specific target site. The changes in hsa-miR-654-5p can play an important role in osteogenic differentiation regulation of hBMSCs.


  • Acheron regulates vascular endothelial proliferation and angiogenesis together with Id1 during wound healing

    by Rongju Sun, Wei Chen, Xiaodong Zhao, Tanshi Li, Qing Song

    RNA binding protein acheron has proved to be either the mediator of integrin‐extracellular matrix interactions or the regulatory factor that participates in vertebrate development, cell differentiation and cell death. We report the role of acheron in vascular endothelial proliferation, angiogenesis and wound healing post‐trauma. Co‐immunoprecipitation showed that Acheron forms a ternary complex with β1 integrin and Id1 in human umbilical vein endothelial cells following stimulation with serious trauma serum. Acheron, vascular endothelial growth factor (VEGF), and β1 integrin mRNA expression was apparently inhibited, and capillary density and wound healing rate also were reduced in Id1‐deficient mice trauma model. Acheron together with Id1 significantly induces VEGF, not CD105 level inhibition by serious trauma serum for 24 h. In conclusion, we have demonstrated that acheron may be an effective mediator of promoting endothelial proliferation, angiogenesis and wound healing probably by regulating VEGF together with Id1. Copyright © 2011 John Wiley & Sons, Ltd.